- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02622659
The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Henan
-
Luohe, Henan, Chine, 462000
- Luohe traditional Chinese medicine hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients diagnosed as acute upper respiratory infection.
- Patients with Traditional Chinese Medicine syndrome of qi deficiency and wind-heat.
- Patients aged 1 to 12 years.
- With course of disease in 48 hours or less.
- Signed informed consent by a Parent or legal guardians.
Exclusion Criteria:
- Patients diagnosed as tonsillitis, bronchitis, bronchiolitis, pneumonia;
- Patients have a history of hyperpyretic convulsion;
- Severe malnutrition, rickets patients and merge the heart, brain, liver, kidney and hematopoietic system and other serious primary diseases;
- The increased of serum creatinine (Cr), blood urea nitrogen (BUN), alanine aminotransferase (ALT), and urinary protein, urine RBC above "+", which can not use the test illness or possibly combined disease conditions to explain;
- Patients with allergic physique (Allergic to above two kinds of substance), allergic to the composition of the preparation or control drug;
- According to the doctors' determination,likely to loss to follow up.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Fuganlin Oral Liquid
Fuganlin Oral Liquid:oral less than 1 years old: 5mL each time and three times a day 1~3 years old: 10mL each time and three times a day 4~6 years old: 10mL each time and four times a day 7~12 years old: 10mL each time and five times a day Xiaoer Jiebiao Oral Liquid placebo:oral 1~2 years old: 5mL each time and twice a day 3~5 years old: 5mL each time and three times a day 6~14 years old: 10mL each time and twice a day |
less than 1 years old: 5mL each time and three times a day 1~3 years old: 10mL each time and three times a day 4~6 years old: 10mL each time and four times a day 7~12 years old: 10mL each time and five times a day
Autres noms:
|
|
Comparateur actif: Xiaoer Jiebiao Oral Liquid
Xiaoer Jiebiao Oral Liquid:oral 1~2 years old: 5mL each time and twice a day 3~5 years old: 5mL each time and three times a day 6~14 years old: 10mL each time and twice a day Fuganlin Oral Liquid placebo:oral less than 1 years old: 5mL each time and three times a day 1~3 years old: 10mL each time and three times a day 4~6 years old: 10mL each time and four times a day 7~12 years old: 10mL each time and five times a day |
1~2 years old: 5mL each time and twice a day 3~5 years old: 5mL each time and three times a day 6~14 years old: 10mL each time and twice a day
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The duration of cold symptoms
Délai: Defined as the time from the onset of the cold to the time achieve a cold cure standard,time average 3 to 7 days
|
Cold diagnostic criteria:
Cold cure criteria:
|
Defined as the time from the onset of the cold to the time achieve a cold cure standard,time average 3 to 7 days
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Cao xia, MD, Chongqing First People's Hospital
- Chercheur principal: Yan yunying, MD, Nanning maternal and Child Health Hospital
- Chercheur principal: Hu suping, MD, Nanchang City Hospital of integrated traditional Chinese and Western Medicine
- Chercheur principal: Wang leping, MD, Changzhou Traditional Chinese Medicine Hospital
- Chercheur principal: Liu Dexing, MD, Liuzhou traditional Chinese medicine hospital
- Chercheur principal: Qi Shihe, MD, Xiangyang Central Hospital
- Chercheur principal: Ding Lijun, MD, Handan traditional Chinese medicine hospital
- Chercheur principal: Yang Liping, MD, Changzhi City People's Hospital
- Chercheur principal: Feng Ziwei, MD, Luohe traditional Chinese medicine hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2012Pro170EKZY
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .